Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs

Japanese Journal of Cancer Research

Volumn 88, Issue 8, 1997, Pages 750-759

  Nagasawa, Kazuki ^a   Ohnishi, Noriaki ^a   Yokoyama, Teruyoshi ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

HL60 cell; Human mononuclear cell; Idarubicin; Transport mechanism

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; IDARUBICIN; PIRARUBICIN;

ARTICLE; CELL STRAIN HL 60; DRUG TRANSPORT; DRUG UPTAKE; ENERGY; HUMAN; HUMAN CELL; LEUKEMIA; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE;

EID: 0030779932     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00447.x     Document Type: Article

References (35)

1. Nagasawa, K., Natazuka, T., Chihara, K., Kitazawa, F., Tsumura, A., Takara, K., Nomiyama, M., Ohnishi, N. and Yokoyama, T. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells. Cancer Chemother. Pharmacol., 37, 297-304 (1996).
2. Nagasawa, K., Natazuka, T., Nomiyama, M., Ohnishi, N. and Yokoyama, T. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin. Biol. Pharm. Bull., 19, 100-105 (1996).
3. Nagasawa, K., Tsumura, A., Nomiyama, M., Ohnishi, N. and Yokoyama, T. Transport mechanism of pirarubicin in human mononuclear cells. Biol. Pharm. Bull., 19, 1203-1209 (1996).
4. Arcamone, F., Bernardi, L., Giardio, P., Patelli, B., Di Marco, A., Casazza, A. M., Pratesi, G. and Reggiani, P. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers. Cancer Treat. Rep., 60, 829-834 (1979).
5. Casazza, A. M. Experimental evaluation of anthracycline analogs. Cancer Treat. Rep., 63, 835-844 (1979).
6. Casazza, A. M., Praziella, G., Giuliani, F. and Di Marco, A. Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori, 66, 549-564 (1980).
7. Kuffel, M. J., Reid, J. M. and Ames, M. M. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother. Pharmacol., 30, 51-57 (1992).
8. Tsuruo, T., Oh-hara, T., Sudo, Y. and Naito, M. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia. Anticancer Res., 13, 357-362 (1993).
9. Fukushima, T., Ueda, T., Uchida, M. and Nakamura, T. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. Int. J. Hematol., 57, 121-130 (1993).
10. Tidefelt, U., Prenkert, M. and Paul, C. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells. Cancer Chemother. Pharmacol., 38, 476-480 (1996).
11. Berman, E., Heller, G., Santorsa, J., McKenzie, S., Gee, T., Kempin, S., Gulati, S., Andreeff, M., Kolitz, J., Garbrilove, J., Reich, L., Mayer, K., Keefe, D., Trainor, K., Schluger, A., Penenberg, D., Raymond, V., O'Reilly, R., Jhanwar, S., Young, C. and Clarkson, B. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 77, 1666-1674 (1991).
12. Mandelli, F., Petti, M. C., Ardia, A., Di Pietro, N., Di Raimondo, F., Ganzina, F., Falconi, E., Geraci, E., Ladogana, S., Latagliata, R., Malleo, C., Nobile, F., Petti, N., Rotoli, B., Specchia, G., Tabilio, A. and Resegotti, L. A randomized clinical trial comparing idarubicin and cytarabine in the treatment of acute non-lymphoid leukemia. A multicentric study from the Italian co-operative group GIMEMA. Eur. J. Cancer, 27, 750-755 (1991).
13. Wiernik, P. H., Banks, P. L. C., Case, D. C. C., Jr., Arlin, Z. A., Periman, P. O., Todd, M. B., Ritch, P. S., Enck, R. E. and Weitberg, A. B. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood, 79, 313-319 (1992).
14. Vogler, W. R., Velez-Garcia, E., Weiner, R. S., Flaum, M. A., Bartolucci, A. A., Omura, G. A., Gerber, M. C. and Banks, P. L. C. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a southeastern cancer study group study. J. Clin. Oncol., 10, 1103-1111 (1992).
15. Reiffers, J., Hugnuet, F., Stoppa, A.-M., Molina, L., Marit, G., Attal, M., Gastaut, J. A., Michallet, M., Lepeu, G., Broustet, A., Pris, J., Maraninchi, D., Hollard, D., Fabères, C., Mercier, M., Hurteloup, P., Danel, P., Tellier, Z. and Berthaud, P. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia, 10, 389-395 (1996).
16. Berman, E. and McBride, M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood, 79, 3267-3273 (1992).
17. Michieli, M., Damiani, D., Michelutti, A., Candoni, A., Masolini, P., Scaggiante, B., Quadrifoglio, F. and Baccarani, M. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica, 79, 500-507 (1994).
18. Toffoli, G., Simine, F., Gigante, M. and Boiocchi, M. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines. Biochem. Pharmacol., 48, 1871-1881 (1994).
19. Hargrave, R. M., Davey, M. W., Davey, R. A. and Kidman, A. D. Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anti-Cancer Drugs, 6, 432-437 (1995).
20. Ross, D. D., Doyle, L. A., Yang, W., Tong, Y. and Comblatt, B. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem. Pharmacol., 50, 1673-1683 (1995).
21. Consoli, U., Priebe, W., Ling, Y.-H., Mahadevia, R., Griffin, M., Zhao, S., Petez-Soler, R. and Andreeff, M. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood, 88, 633-644 (1996).
22. Tarasiuk, J., Foucrier, J. and Garnier-Suillerot, A. Cell cycle dependent uptake and release of anthracycline by drug-resistant and drug-sensitive human leukaemic K562 cells. Biochem. Pharmacol., 45, 1801-1808 (1993).
23. Nagasawa, K., Yokoyama, T., Ohnishi, N., Iwakawa, S., Okumura, K., Kosaka, Y., Sano, K., Murakami, R. and Nakamura, H. Pharmacokinetics of pirarubicin in pediatric patients. J. Pharmacobio-Dyn., 14, 222-230 (1991).
24. Nagasawa, K., Nomiyama, M., Ohnishi, N., Yokoyama, T., Iwakawa, S. and Okumura, K. Transport mechanism of anthracycline derivatives in rat polymorphonuclear leukocytes: uptake and efflux of pirarubicin. Biol. Pharm. Bull., 17, 696-700 (1994).
25. Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T. A pharmacokinetic analysis program (MULTI) for micro-computer. J. Pharmacobio-Dyn., 4, 879-885 (1981).
26. Nagasawa, K., Takara, K., Nomiyama, M., Ohnishi, N. and Yokoyama, T. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells. Biol. Pharm. Bull., 19, 971-976 (1996).
27. Rivory, L. P., Avent, K. M. and Pond, S. M. Effects of lipophilicity and protein binding on the hepatocellular uptake and hepatic disposition of two anthracyclines, doxorubicin and iododoxorubicin. Cancer Chemother. Pharmacol., 38, 439-445 (1996).
28. Terasaki, T., Iga, T., Sugiyama, Y. and Hanano, M. Experimental evidence of characteristic tissue distribution of adriamycin. Tissue DNA concentration as a determinant. J. Pharm. Pharmacol., 34, 597-600 (1982).
29. Terasaki, T., Iga, T., Sugiyama, Y. and Hanano, M. Interaction of doxorubicin with nuclei isolated from rat liver and kidney. J. Pharm. Sci., 73, 524-528 (1994).
30. Terasaki, T., Iga, T., Sugiyama, Y. and Hanano, M. Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: interorgan and interspecies variation of tissue-to-plasma partition coefficients in rats, rabbits, and guinea pigs. J. Pharm. Sci., 73, 1359-1363 (1984).
31. Weaver, J. L., Pine, P. S., Aszalos, A., Schoenlein, P. V., Currier, S. J., Padmanabhan, R. and Gottesman, M. M. Laser scanning and confocal microscopy of daunorubicin, and rhodamine 123 in multidrug resistant cells. Exp. Cell Res., 196, 323-329 (1991).
32. Slapak, C. A., Lecerf, J.-M., Daniel, J. C. and Levy, S. B. Energy-dependent accumulation of daunorubicin into subcellular compartments of human leukemia cells and cytoplasts. J. Biol. Chem., 267, 10638-10644 (1992).
33. Rutherford, A. V. and Willingham, M. C. Ultrastructural localization of daunomycin in multidrug-resistant cultured cells with modulation of the multidrug transporter. J. Histochem. Cytochem., 41, 1573-1577 (1993).
34. Gieseler, F., Biersack, H., Briden, T., Manderscheid, J. and Nüßler, V. Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding. Ann. Hematol., 69, S13-S17 (1994).
35. Seidel, A., Hasmann, M., Löser, R., Bunge, A., Schaefer, B., Herzig, I., Steidtmann, K. and Dietel, M. Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells. Virchows Arch., 426, 249-256 (1995).